SCHEMBL2348523

SCHEMBL2348523

CCCCCCCC/C=C\CCCCCCCC(=O)OC(CC(O)CO)C(CO)OCCCCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.57
PRKCA P17252 2/20 0.52
PRKCE Q02156 1/20 0.52
PRKCQ Q04759 1/20 0.52
PRKCD Q05655 1/20 0.52
SELP P16109 1/20 0.49
FAAH O00519 3/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
DAGLA Q9Y4D2 1/20 0.48
S1PR1 P21453 1/20 0.48
LPAR1 Q92633 6/20 0.47
LPAR4 Q99677 3/20 0.47
LPAR2 Q9HBW0 3/20 0.47
LPAR3 Q9UBY5 3/20 0.47
ENPP2 Q13822 2/20 0.46
LPAR5 Q9H1C0 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1823472 0.85 DGKA (0.62) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL3718763 0.85 DGKA (0.62) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL7714599 0.85 DGKA (0.73) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL1926653 0.84 DGKA (0.61) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL27546892 0.84 PRKCA (0.55) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL8149967 0.84 DGKA (0.57) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL16612104 0.82 PRKCA (0.68) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL1273212 0.82 PRKCA (0.55) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL1273757 0.82 PRKCA (0.55) DGKAPRKCAPRKCEPRKCQPRKCD
SCHEMBL27763371 0.81 DGKA (0.67) DGKAPRKCAPRKCEPRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10238700-B2 Oncolytic virus adjunct therapy with agents that increase virus infectivity GENELUX CORPORATION (US) 2019-03-26 US disclosed
US-20180344666-A1 VITAMIN K-ENRICHED LIPID EMULSION FORMULATIONS FOR THE TREATMENT OF PHARMA TOXICITY RESQ PHARMA LLC 2018-12-06 US disclosed
EP-3373909-A1 VITAMIN K-ENRICHED LIPID EMULSION FORMULATIONS FOR THE TREATMENT OF PHARMA TOXICITY RESQ Pharma Inc. (US) 2018-09-19 EP disclosed
WO-2017083780-A1 VITAMIN K-ENRICHED LIPID EMULSION FORMULATIONS FOR THE TREATMENT OF PHARMA TOXICITY RESQ PHARMA INC. (US) 2017-05-18 WO disclosed
US-20160339066-A1 ONCOLYTIC VIRUS ADJUNCT THERAPY WITH AGENTS THAT INCREASE VIRUS INFECTIVITY GENELUX CORPORATION 2016-11-24 US disclosed
WO-2015103438-A2 ONCOLYTIC VIRUS ADJUNCT THERAPY WITH AGENTS THAT INCREASE VIRUS INFECTIVITY GENELUX CORPORATION (US) 2015-07-09 WO disclosed
US-8834919-B2 Lipid emulsions in the treatment of systemic poisoning RESQ PHARMA, INC. 2014-09-16 US disclosed
US-7989502-B2 Intranasal delivery of modafinil SRI INTERNATIONAL (US) 2011-08-02 US disclosed
US-20100204334-A1 Intranasal Delivery of Modafinil SRI International and Health Partners Research Foundation 2010-08-12 US disclosed
US-20080021411-A1 Lipid Emulsions in the Treatment of Systemic Poisoning RESQ PHARMA, INC. 2008-01-24 US disclosed
US-7261903-B1 Lipid emulsions in the treatment of systemic poisoning WEINBERG GUY 2007-08-28 US disclosed
WO-1999043301-A1 LIPID EMULSIONS IN THE TREATMENT OF SYSTEMIC POISONING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1999-09-02 WO disclosed